substantial evidence has shown the function of ILK, reflected in the term of ILK addiction 40 in several kinds of cancers. 16-22 Equally crucial, the ILK inhibitor 54 provides a proof of principle that ILK kinase Linifanib clinical trial activity could be qualified to suppress tumor cell development via inhibition of signaling pathways mediated by Akt and YB But, as recent reports show that 54 as one representative lacks in vivo anti-tumor activity,41 and that it is not specific for ILK,29 there’s an urgency to build up novel ILK inhibitors with greater potency and specificity. Compound 22 was initially identified through the screening of an in house focused compound selection by immunoblotting against Akt phosphorylation at Ser 473 versus Thr 308. Radiometric assays using immunoprecipitated ILK from PC 3 cells demonstrated the ability of 22 to prevent ILK kinase exercise with IC50 of 0. 6 uM, which correlated with its high-potency in suppressing the levels of Ser 473 Akt and other ILK substrates in cancer cells. Similarly Ribonucleic acid (RNA) essential, 22 showed a higher degree of specificity against a panel of recombinant kinases. Particularly, no significant inhibition by 22 was observed in a number of signaling kinases, including PDK1, Akt, mTOR, GSK3B, FAK, cKit, EGFR, and FAK. One more line of evidence for that ILK qualified activity of 22 was its repressive impact on the protein and mRNA levels of the transcription/translation aspect YB 1 and its representative targets HER2 and EGFR. As improved expression and nuclear localization of YB 1 is connected with increased expansion, multi-drug opposition, cyst aggressiveness, and poor prognosis in several forms of cancers by stimulating the expression of a wide selection of growth-promoting genes,42 the capability of 22 to a target natural product library YB 1 expression is noteworthy. Evidence suggests that 22 mediates its antiproliferative result through the induction of both apoptosis and autophagy in PC 3 cells. Our data suggest that 22 induced autophagy through ILK inhibition, which occurred at concentrations below the limit that our show is needed for causing apoptosis in 22 treated cells. Moreover, as Atg5 silencing attenuated autophagy and the suppressive influence of 22 on cell viability, this induction is integral to 22s antiproliferative activity, specially at low levels. Taken together, this broad-spectrum of elements underlies the therapeutic potential of 22 in cancer therapy, as demonstrated by its in vivo effectiveness as an individual agent in PC 3 xenograft tumefaction growth. To conclude, our data show that 22 is just a story, orally bioavailable ILK chemical with a definite mode of action that inhibits tumor cell growth by modulating multiple signaling pathways associated with tumor development and oncogenesis.